Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Smoking-by-genotype interaction in type 2 diabetes risk and fasting glucose

  • Peitao Wu
  • , Denis Rybin
  • , Lawrence F. Bielak
  • , Mary F. Feitosa
  • , Nora Franceschini
  • , Yize Li
  • , Yingchang Lu
  • , Jonathan Marten
  • , Solomon K. Musani
  • , Raymond Noordam
  • , Sridharan Raghavan
  • , Lynda M. Rose
  • , Karen Schwander
  • , Albert V. Smith
  • , Salman M. Tajuddin
  • , Dina Vojinovic
  • , Najaf Amin
  • , Donna K. Arnett
  • , Erwin P. Bottinger
  • , Ayse Demirkan
  • Jose C. Florez, Mohsen Ghanbari, Tamara B. Harris, Lenore J. Launer, Jingmin Liu, Jun Liu, Dennis O. Mook-Kanamori, Alison D. Murray, Mike A. Nalls, Patricia A. Peyser, André G. Uitterlinden, Trudy Voortman, Claude Bouchard, Daniel Chasman, Adolfo Correa, Renée de Mutsert, Michele K. Evans, Vilmundur Gudnason, Caroline Hayward, Linda Kao, Sharon L.R. Kardia, Charles Kooperberg, Ruth J.F. Loos, Michael M. Province, Tuomo Rankinen, Susan Redline, Paul M. Ridker, Jerome I. Rotter, David Siscovick, Blair H. Smith, Cornelia van Duijn, Alan B. Zonderman, D. C. Rao, James G. Wilson, Josée Dupuis, James B. Meigs, Ching Ti Liu, Jason L. Vassy

Producción científica: Articlerevisión exhaustiva

16 Citas (Scopus)

Resumen

Smoking is a potentially causal behavioral risk factor for type 2 diabetes (T2D), but not all smokers develop T2D. It is unknown whether genetic factors partially explain this variation. We performed genome-environment-wide interaction studies to identify loci exhibiting potential interaction with baseline smoking status (ever vs. never) on incident T2D and fasting glucose (FG). Analyses were performed in participants of European (EA) and African ancestry (AA) separately. Discovery analyses were conducted using genotype data from the 50,000-single-nucleotide polymorphism (SNP) ITMAT-Broad-CARe (IBC) array in 5 cohorts from from the Candidate Gene Association Resource Consortium (n = 23,189). Replication was performed in up to 16 studies from the Cohorts for Heart Aging Research in Genomic Epidemiology Consortium (n = 74,584). In meta-analysis of discovery and replication estimates, 5 SNPs met at least one criterion for potential interaction with smoking on incident T2D at p<1x10-7 (adjusted for multiple hypothesis-testing with the IBC array). Two SNPs had significant joint effects in the overall model and significant main effects only in one smoking stratum: rs140637 (FBN1) in AA individuals had a significant main effect only among smokers, and rs1444261 (closest gene C2orf63) in EA individuals had a significant main effect only among nonsmokers. Three additional SNPs were identified as having potential interaction by exhibiting a significant main effects only in smokers: rs1801232 (CUBN) in AA individuals, rs12243326 (TCF7L2) in EA individuals, and rs4132670 (TCF7L2) in EA individuals. No SNP met significance for potential interaction with smoking on baseline FG. The identification of these loci provides evidence for genetic interactions with smoking exposure that may explain some of the heterogeneity in the association between smoking and T2D.

Idioma originalEnglish
Número de artículoe0230815
PublicaciónPLoS ONE
Volumen15
N.º5
DOI
EstadoPublished - may 2020

Nota bibliográfica

Publisher Copyright:
© This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Financiación

WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. The grant funding of WHI are R21 HL123677, R56 DK104806 and R01 MD012765 to NF. The FamHS was funded by R01HL118305 and R01HL117078 NHLBI grants, and 5R01DK07568102 and 5R01DK089256 NIDDK grant." and "The Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study was supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health (project # Z01-AG000513 and human subjects protocol number 09-AGN248). Support for GENOA was provided by the National Heart, Lung and Blood Institute (HL119443, HL087660, HL054464, HL054457, and HL054481) of the National Institutes of Health. Ruth loos is supported by the NIH (R01DK110113, U01HG007417, R01DK101855, R01DK107786). The Rotterdam Study GWAS datasets are supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), and the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project nr. 050-060-810. The ERF study as a part of EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006- 01947) and also received funding from the European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413 by the European Commission under the programme "Quality of Life and Management of the Living Resources" of 5th Framework Programme (no. QLG2-CT-2002- 01254). The ERF study was further supported by ENGAGE consortium and CMSB. Highthroughput analysis of the ERF data was supported by joint grant from Netherlands Organisation for Scientific Research and the Russian Foundation for Basic Research (NWORFBR 047.017.043).ERF was further supported by the ZonMw grant (project 91111025), and this work was partially supported by the National Heart, Lung and Blood Institute's Framingham Heart Study (Contract No. N01-HC25195) and its contract with Affymetrix, Inc for genotyping services (Contract No. N02-HL-6-4278). This study is also supported by National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) R01 DK078616 to Drs. Meigs, Dupuis and Florez, NIDDK K24 DK080140 to Dr. Meigs, and a Doris Duke Charitable Foundation Clinical Scientist Development Award to Dr. Florez. The HERITAGE Family Study was supported by National Heart, Lung, and Blood Institute grant HL-45670. The Women's Genome Health Study is supported by the National Heart, Lung, and Blood Instutute (HL043851 and HL080467) and the National Cancer Institute (CA047988 and UM1CA182913). Additional support for endpoint collection was provided by the National Heart, Lung, and Blood Institute under ARRA funding (HL099355). HyperGEN (Hypertension Genetic Epidemiology Network): The hypertension network is funded by cooperative agreements (U10) with NHLBI: HL54471, HL54472, HL54473, HL54495, HL54496, HL54497, HL54509, HL54515, and 2 R01 HL55673- 12. The AGES study has been funded by NIH contracts N01-AG-1-2100 and 271201200022C. Caroline Hayward is supported by an MRC University Unit Programme Grant MC_UU_00007/10 (QTL in Health and Disease)”and “Generation Scotland received core funding from the Chief Scientist Office of the Scottish Government Health Directorate CZD/16/6, the Scottish Funding Council HR03006 and the Wellcome Trust through a Strategic Award (reference 104036/Z/14/Z) for Stratifying Resilience and Depression Longitudinally (STRADL). Genotyping was funded by the UK's Medical Research Council. Jose C. Florez, NIDDK K24 DK110550 The MESA project is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420, UL1-TR-001881, and DK063491. Additionally, one or more authors are affiliated with the following commercial entities: Interleukin Genetics, GlaxoSmithKline, Daiichi-Sankyo, AstraZeneca, Data Tecnica International LLC, Illumina Inc., University of California Healthcare, Janssen Pharmaceuticals, Goldfinch Bio, and Novo Nordisk. Please see the Competing Interests Statement for additional details. The funders provided support in the form of salaries for authors but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.

FinanciadoresNúmero del financiador
Chief Scientist Office of the Scottish Government Health DirectorateCZD/16/6
Data Tecnica International LLC
ENGAGE consortium
EUROSPAN
Illumina Inc.
NWORFBR047.017.043
Netherlands Consortium for Healthy Aging050-060-810
Netherlands Genomics Initiative
Netherlands Organisation of Scientific Research NWO175.010.2005.011, 911-03-012
Quality of Life and Management of the Living Resources” of 5th Framework ProgrammeQLG2-CT-2002- 01254
RIDE2
Research Institute for Diseases in the Elderly014-93-015
VA San Diego Healthcare System, Center of Excellence for Stress and Mental Health Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA
National Institutes of Health (NIH)U01HG007417
National Institutes of Health (NIH)
U.S. Department of Health and Human ServicesHHSN268201100004C, R01 MD012765, 5R01DK07568102, HHSN268201100003C, R56 DK104806, 5R01DK089256, R21 HL123677, HHSN271201100004C, HHSN268201100002C, HHSN268201100046C, HSN268201100001C
U.S. Department of Health and Human Services
National Institute on Aging09-AGN248, Z01-AG000513
National Institute on Aging
National Heart, Lung, and Blood Institute (NHLBI)HL087660, N01-AG-1-2100, HL043851, HL54515, HL119443, R01HL117078, HL54509, R01HL118305, HL054457, HL080467, 2 R01 HL55673, 271201200022C, HL054481, HL54472, HL54473, HL54495, HL54496, HL54497, HL054464, HL54471
National Heart, Lung, and Blood Institute (NHLBI)
National Childhood Cancer Registry – National Cancer InstituteHL099355, U10, CA047988, UM1CA182913
National Childhood Cancer Registry – National Cancer Institute
National Institute of Diabetes and Digestive and Kidney DiseasesNIDDK K24 DK080140, R01DK110113, R01DK107786, R01DK101855, R01 DK078616
National Institute of Diabetes and Digestive and Kidney Diseases
Doris Duke Charitable FoundationHL-45670
Doris Duke Charitable Foundation
Janssen Pharmaceuticals
Wellcome Trust104036/Z/14/Z
Wellcome Trust
Seventh Framework ProgrammeHEALTH-F4-2007-201413
Seventh Framework Programme
Virginia Marine Resources CommissionMC_UU_00007/10
Virginia Marine Resources Commission
Medical Research CouncilUL1-TR-001881, K24 DK110550, UL1-TR-001079, UL1-TR-001420, UL1-TR-000040, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95160, N01-HC-95169, N01-HC-95159, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, 75N92020D00002, DK063491, HHSN268201500003I
Medical Research Council
Scottish Funding Council, United KingdomHR03006
Scottish Funding Council, United Kingdom
European Commission
ZonMw Memorabel91111025, N01-HC25195, N02-HL-6-4278
ZonMw Memorabel
Russian Foundation for Basic Research
Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Novo Nordisk A/S
Seventh Framework Programme
Sixth Framework Programme018947, LSHG-CT-2006- 01947
Sixth Framework Programme
Centre for Medical Systems Biology

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • General

    Huella

    Profundice en los temas de investigación de 'Smoking-by-genotype interaction in type 2 diabetes risk and fasting glucose'. En conjunto forman una huella única.

    Citar esto